BACKGROUND: In patients with systemic sclerosis (SSc), the relationship between innate immune activation, represented by increased expression of interferon (IFN)-regulated genes, and vascular injury/activation, manifest by increased endothelin-1 (ET-1), endothelin converting enzyme-1 (ECE1) and intercellular adhesion molecule-1, is uncertain. OBJECTIVE: To investigate the potential roles of innate immune ligands in both these pathogenic pathways. METHODS: The effect of known Toll-like receptor (TLR) ligands was tested in vitro on dermal microvascular and pulmonary arterial endothelial cells, and on dermal fibroblasts cultured from healthy controls and patients with SSc. To test the effect of double-stranded RNA (dsRNA) on vascular activation/injury in vivo, polyinosinic/polycytidylic acid (poly(I:C)) was administered continuously over 7 days by subcutaneous osmotic pump. RESULTS: dsRNA/poly(I:C), but not other TLR ligands, highly stimulated ET-1 protein and mRNA (EDN1), as well as intercellular adhesion molecule-1 (ICAM-1) and IFN-regulated MX2, by endothelial cells and dermal fibroblasts. Poly(I:C) induced EDN1, ECE1, and ICAM-1 mRNA expression in poly(I:C) treated skin. Poly(I:C)-induced EDN1, ECE1 and MX2 was not blocked in mice with the type I IFN receptor deleted. However, poly(I:C)-induced EDN1 and ECE1, but not poly(I:C)-induced ICAM-1 expression was blocked in mice with the TLR3 signalling protein TRIF/TICAM-1 deleted. CONCLUSION: Together these data show that the dsRNA can regulate genes associated with vascular activation, as seen in SSc, that type I IFNs do not mediate these effects, and that EDN1 and ECE1 but not ICAM-1 activation is mediated by TLR3.
BACKGROUND: In patients with systemic sclerosis (SSc), the relationship between innate immune activation, represented by increased expression of interferon (IFN)-regulated genes, and vascular injury/activation, manifest by increased endothelin-1 (ET-1), endothelin converting enzyme-1 (ECE1) and intercellular adhesion molecule-1, is uncertain. OBJECTIVE: To investigate the potential roles of innate immune ligands in both these pathogenic pathways. METHODS: The effect of known Toll-like receptor (TLR) ligands was tested in vitro on dermal microvascular and pulmonary arterial endothelial cells, and on dermal fibroblasts cultured from healthy controls and patients with SSc. To test the effect of double-stranded RNA (dsRNA) on vascular activation/injury in vivo, polyinosinic/polycytidylic acid (poly(I:C)) was administered continuously over 7 days by subcutaneous osmotic pump. RESULTS: dsRNA/poly(I:C), but not other TLR ligands, highly stimulated ET-1 protein and mRNA (EDN1), as well as intercellular adhesion molecule-1 (ICAM-1) and IFN-regulated MX2, by endothelial cells and dermal fibroblasts. Poly(I:C) induced EDN1, ECE1, and ICAM-1 mRNA expression in poly(I:C) treated skin. Poly(I:C)-induced EDN1, ECE1 and MX2 was not blocked in mice with the type IIFN receptor deleted. However, poly(I:C)-induced EDN1 and ECE1, but not poly(I:C)-induced ICAM-1 expression was blocked in mice with the TLR3 signalling protein TRIF/TICAM-1 deleted. CONCLUSION: Together these data show that the dsRNA can regulate genes associated with vascular activation, as seen in SSc, that type I IFNs do not mediate these effects, and that EDN1 and ECE1 but not ICAM-1 activation is mediated by TLR3.
Authors: D Omagari; Y Mikami; H Suguro; K Sunagawa; M Asano; E Sanuki; I Moro; K Komiyama Journal: Clin Exp Immunol Date: 2009-03-04 Impact factor: 4.330
Authors: Daniel Kim; Anders Peck; Deanna Santer; Prashant Patole; Stephen M Schwartz; Jerry A Molitor; Frank C Arnett; Keith B Elkon Journal: Arthritis Rheum Date: 2008-07
Authors: Caglar Cekic; Carolyn R Casella; Chelsea A Eaves; Atsushi Matsuzawa; Hidenori Ichijo; Thomas C Mitchell Journal: J Biol Chem Date: 2009-09-15 Impact factor: 5.157
Authors: Markus Wörnle; Matthias Sauter; Kathrin Kastenmüller; Andrea Ribeiro; Maximilian Roeder; Holger Schmid; Florian Krötz; Thomas Mussack; Roland Ladurner; Thomas Sitter Journal: Mol Cell Biochem Date: 2008-11-13 Impact factor: 3.396
Authors: S Soldano; P Montagna; B Villaggio; A Parodi; G Gianotti; A Sulli; B Seriolo; M E Secchi; M Cutolo Journal: Ann Rheum Dis Date: 2008-10-24 Impact factor: 19.103
Authors: Karen A Cavassani; Makoto Ishii; Haitao Wen; Matthew A Schaller; Pamela M Lincoln; Nicholas W Lukacs; Cory M Hogaboam; Steven L Kunkel Journal: J Exp Med Date: 2008-10-06 Impact factor: 14.307
Authors: Lenny van Bon; Alsya J Affandi; Jasper Broen; Romy B Christmann; Renoud J Marijnissen; Lukasz Stawski; Giuseppina A Farina; Giuseppina Stifano; Allison L Mathes; Marta Cossu; Michael York; Cindy Collins; Mark Wenink; Richard Huijbens; Roger Hesselstrand; Tore Saxne; Mike DiMarzio; Dirk Wuttge; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Maureen Mayes; Yanhui Deng; Joost P H Drenth; Jacqueline de Graaf; Martin den Heijer; Cees G M Kallenberg; Marc Bijl; Arnoud Loof; Wim B van den Berg; Leo A B Joosten; Vanessa Smith; Filip de Keyser; Rafaella Scorza; Claudio Lunardi; Piet L C M van Riel; Madelon Vonk; Waander van Heerde; Stephan Meller; Bernhard Homey; Lorenzo Beretta; Mark Roest; Maria Trojanowska; Robert Lafyatis; Timothy R D J Radstake Journal: N Engl J Med Date: 2013-12-18 Impact factor: 91.245
Authors: Stefania Lenna; Izabela Chrobak; G Alessandra Farina; Fernando Rodriguez-Pascual; Santiago Lamas; Robert Lafyatis; Raffaella Scorza; Maria Trojanowska Journal: PLoS One Date: 2013-02-18 Impact factor: 3.240